Olmutinib: Additional Phase I/II data

Additional data from 70 evaluable patients with T790M EGFR mutation-positive NSCLC who developed resistance to previous EGFR TKIs in the open-label, South Korean Phase I/II HM-EMSI-101 trial showed that

Read the full 295 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE